Please assess the completion status of the following clinical trial:

Trial Title: Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged between 19 and 35 years, nonsmokers~* Body mass index between 15th and 85th percentile (Must et al. 1991)~* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant~* Normal ophthalmic findings, ametropia \< 3 dpt.~Exclusion Criteria:~* Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study~* Treatment in the previous 3 weeks with any drug~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs~* Blood donation during the previous 3 weeks~* Ametropia \>= 3 dpt~* Iris bicolor

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Latanoprost 0.005%, Xalatan®
- 2 (Type: PLACEBO_COMPARATOR): Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).